JPH0692313B2 - Method for producing cell activator - Google Patents

Description

TECHNICAL FIELD The present invention relates to a method for producing a cell activating agent effective for treating a disease caused by inactivation or aging of cells.
More specifically, the present invention is directed to so-called geriatric diseases such as Alzheimer-type senile dementia, cerebrovascular dementia, cerebrovascular disorder (cerebral hemorrhage, cerebral embolism, cerebral infarction), heart disease, kidney disease, cataract, etc. The present invention relates to a method for easily and efficiently producing a cell activator which exhibits remarkable effects and does not accompany infectious diseases.

It is known that the introduction of new DNA into inactivated cells activates the cells, and this phenomenon has been utilized to date by utilizing the brain, organs and testis of animals such as monkeys, cows and pigs. A large number of cell activators mainly composed of cells extracted from the above have been proposed.

However, the cells that make up the human body are diverse in each type of organ tube, and the behavior of these externally introduced DNAs is also different. However, there is a problem that even if it is effective, its activation is incomplete due to the rejection reaction, and the cure of a predetermined disease is not always completely performed.

Moreover, since these cell activating agents use cells of different animals, they lack affinity in the human body and are unavoidable with some side effects.

Therefore, in the field of clinical treatment, particularly in the field of treatment of senile diseases, there has been a demand for the appearance of a cell activating agent that acts universally on each organ of the human body and has no side effects.

The present inventor has conducted research to meet such demands,
Although it was previously formulated using sperm sperm as a source of DNA, it was found that inactivated or aged cells in all organs in the human body can be rapidly treated regardless of the blood group of the subject and the blood group of the patient. It has been found that it can be activated for a long period of time and is extremely effective in the treatment of various geriatric diseases that have been difficult to cure until now, and that it has no side effects at all. When using such human sperm semen as a cell activating agent, the most important thing is that even if the semen supplier has an infectious disease or an infectious disease, it can be transmitted to a patient (user) or Focusing on the point of not being infected, a method was proposed in which the semen was sterilized by a pasteurization method at a low temperature in the range of 62 to 65 ° C and then used.

However, in such a pasteurization method, when the semen is contaminated with a heat-resistant pathogen such as hepatitis virus, the pathogen cannot be sterilized sufficiently, resulting in viral hepatitis or the like during the production of the cell activating agent. The pathogen of the infectious disease was not escaped.

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention Under the circumstances, the present invention provides a parenteral cell activator derived from human semen, which is highly effective against various senile diseases without any infectious diseases. The present invention has been made for the purpose of providing a method for producing.

Means for Solving the Problems The present inventor has conducted various studies to produce a parenteral cell activating agent having the above-mentioned preferable characteristics, and a hepatitis virus, which is a typical example of a heat-resistant pathogen, is about 100 ° C. It is noted that when it is heated in, it is killed in about 5 minutes for hepatitis A and non-A non-B hepatitis viruses and about 15 minutes for hepatitis B virus. By using it afterwards, sterilization is sufficiently performed while maintaining the cell activating capacity without being impaired, and further, it consists of the plasma components such as seminal plasma and sperm that make up about 90% of the heat-treated in this way. It was found that the desired effect can be further enhanced by subjecting semen to separation treatment by a centrifuge to separate and remove the seminal plasma to obtain a cell component, and using only this cell component as an active ingredient. Based on knowledge The has been completed.

That is, the present invention is a parenteral characterized in that human sperm semen is heat-sterilized at a temperature in the range of 100 to 110 ° C. for 5 to 20 minutes, and then seminal plasma is separated and removed to obtain only cell components. A method for producing a cell activating agent is provided.

Hereinafter, the present invention will be described in detail.

As the sperm semen used in the present invention, that collected from a healthy human boy under aseptic conditions is used. In this case, it is preferable to collect from persons in their late teens to thirties who have the highest cell activity, but older persons may be used as long as they are healthy.

In normal semen collected in this way, 3 × 10 ⁷ /
cc ~ 3 x 10 ⁸ / cc sperm is included.

This semen is usually a fructose aqueous solution or a glycerin aqueous solution.
It is used after diluting ~ 20 times. This semen has a peculiar odor with a milky white jelly immediately after collection, but when left for 20 to 30 minutes, it becomes liquid due to the action of the enzyme in the semen,
Creates liquidity.

In the method of the present invention, it is necessary to heat-treat the semen at a temperature in the range of 100 to 110 ° C. for 5 to 20 minutes to sterilize it, and then separate and remove seminal plasma to obtain a cell component.

The heat treatment may be performed on the semen before being diluted with the fructose aqueous solution or the glycerin aqueous solution, or may be performed on the diluted one, and the heat treatment temperature is less than 90 ° C has a bactericidal effect on heat-resistant pathogens. It is not sufficient, and if the temperature exceeds 110 ° C, sperm may be altered.

The separation and removal treatment is usually a diluting solution, for example, a fructose aqueous solution,
It is carried out by adding a glycerin aqueous solution and the like and then centrifuging with a centrifuge. According to this centrifugation method, cell components can be easily and efficiently obtained without damaging or damaging the cell components. In this centrifugation, the rotation speed is usually 2000 rpm or more, preferably 3000 r
pm or higher is used. The seminal plasma separated in this way is discarded and only the cellular components are used. Most of this cellular component is sperm, which is meiotic DNA, and occasionally epithelial cells in the urethra are present, but there is no particular problem.

The cell component thus obtained is preferably stored in liquid nitrogen in advance so that it can be obtained immediately when necessary. In particular, it is preferable to store ampoules or capsules packed in liquid nitrogen so as to be stored for each dose. For example, an appropriate amount of glycerin is added to the above-mentioned cellular components, and this liquid is put into a capsule of about 1 ml volume. Fill it and store the capsule in liquid nitrogen.

Sperm contains about half each of protein and DNA, and DNA is strong and hardly changes with heat, but sperm often changes its shape when it is heated too much, that is, it has no tail, the tail is shortened. There are many things, large ones with a circular shape, smaller ones overall, and a few with a tail, and sperm motility does not occur. The cell activating agent obtained under the bactericidal conditions in the method of the present invention does not cause any side effect.

The cell activating agent obtained by the method of the present invention needs to be administered parenterally, and no effect is obtained by oral administration.

Parenteral administration is usually performed by subcutaneous injection or intramuscular injection, but in an emergency, intravenous injection may be performed.

The dose of the cell activating agent is usually 0.1 to 10 on a semen basis.
0.5 ml range, 1 to 1 weekly intervals for mild patients
The effect was observed after two doses, and even in severely ill patients, a clear improvement in symptoms was observed after about 4 to 10 doses. Moreover, no side effects were observed even after 337 subcutaneous or intramuscular injections for about 7 years, and it has been confirmed that it can be used safely.

Effects of the invention Cell activating agents obtained by the method of the present invention, for example, Alzheimer-type senile dementia, cerebrovascular dementia, cerebrovascular disease (cerebral hemorrhage, cerebral embolism, cerebral infarction) and mild cerebral hemorrhage, and their sequelae. Based on various symptoms, such as dizziness, headache, head weight, paralysis of limbs, speech disorder and numbness,
Benign prostatic hyperplasia, senile eye pain, senile fly mosquito (cataract),
It has excellent therapeutic effects on impotence, kidney damage, etc., is also effective in preventing cerebral hemorrhage, suppresses the progression of cancer, prevents metastasis, and has no side effects. In the semen, the tubercle bacillus from its supplier,
Even if it contains spirochetes, gonococci, pyogenes, fungi, rickettsiae, chlamydia, viruses such as hepatitis virus, and protozoa, it does not cause any of these infectious diseases. It is suitable.

EXAMPLES Next, the present invention will be described in more detail by way of examples.

Example 5% of sperm semen collected from a healthy young male (33 years old)
Dilute with 20 ml of fructose aqueous solution, heat sterilize at 100 ℃ for 20 minutes,
It was centrifuged at 4 ° C. for 30 minutes to separate and remove seminal plasma, and 16 ml of an aqueous glycerin solution was added to the remaining cell components and mixed well.

10 ml of healthy males and 5 females of mice were subcutaneously injected with 1 ml of an aqueous solution of glycerin (containing approximately 18 million sperms) of this cell component, and 1 mouse was subcutaneously injected with 1 ml of an aqueous glycerin solution as a control.

As a result, all the mice injected with the sterilized cell components did not show any change even after one month or more, and were healthy.

From this, it was confirmed that the sterilized cell component can be used similarly to the control. The minimum lethal dose at this time is 10 g / kg or more.

Application example Semen collected from a healthy boy (33 years old) under aseptic conditions
After leaving 3 ml for 20 to 30 minutes, dilute it with 10 ml of 5% fructose aqueous solution, heat sterilize at 100 ° C for 20 minutes, and then add 5% fructose aqueous solution 1
0 ml was added, and this was put into four centrifugal precipitation glass tubes in equal amounts and centrifuged at a temperature of 4 ° C. and a rotation speed of 3500 rpm for 30 minutes to separate and remove seminal plasma to precipitate cell components. Glycerin (4 ml) was added to a glass tube for centrifugal precipitation, mixed well, and then filled in a plastic capsule of 1 ml to prepare a cell activating agent.

The cell activating agent thus prepared is subcutaneously or intramuscularly injected to various geriatric patients once or once a week.
It was performed once a month and the progress was observed. The results are shown in the table below.

Each patient was examined for urine, blood, liver function, renal function, electrocardiogram, etc., and examined for side effects, but no side effects were observed.

Claims (1)

[Claims] 1. A parenteral cell characterized by sterilizing human sperm semen at a temperature in the range of 100 to 110 ° C. for 5 to 20 minutes and then separating and removing seminal plasma to obtain only cell components. Method for producing activator.